Re-inventing tumor targeting

Best-in-class, TSL-based tumor targeting.

Explore the science behind Thermosome’s tumor targeting

Setting a new standard for the treatment of locally advanced soft tissue sarcoma.

Explore Thermosome’s pipeline

Experienced team of biotech entrepreneurs.

Get to know Thermosome’s team

First clinical data presented at CTOS 2024 Annual Meeting.

Download pdf

Thermosome is a drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a new tumor targeting concept, which allows for increased local drug concentrations to achieve improved clinical treatment efficacy.

Latest news

Thermosome Initiates Final Dose Level in Phase I Trial of Lead Compound THE001

Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001

Thermosome announces the appointment of Dr. Sabine Hauck as Chief Technology Officer (CTO)

more news

18th Annual European Life Sciences CEO Forum

February 26–27, 2025
Zurich, Switzerland

more Events